CJC-1295 + Epitalon Stack: Complete Protocol for Women

What Is the CJC-1295 + Epitalon Stack?

Stacking CJC-1295 with Epitalon means using both peptides on overlapping or sequential cycles to target two distinct but related biological systems: growth hormone (GH) secretion and cellular aging mechanisms. The idea is that optimizing GH pulsatility while simultaneously supporting telomere biology and pineal function produces additive benefits for sleep quality, lean mass, recovery, and longevity markers.

Neither peptide is approved by the FDA for any therapeutic indication. Both circulate in the compounded-pharmacy and research-chemical markets. The evidence base is heavily animal-derived, and the evidence gap in women specifically is wide. Every claim in this article is labeled by its source type.

CJC-1295: What It Does in the Female Body

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Unlike native GHRH, which has a half-life of roughly 7 minutes, CJC-1295 with drug affinity complex (DAC) has an estimated half-life of 6-8 days in human subjects. The non-DAC version (often called modified GRF 1-29) acts for 30-45 minutes, which is closer to physiologic pulsatility.

Women's GH axis differs from men's in ways that matter for dosing. Healthy premenopausal women secrete more GH per 24-hour period than age-matched men, largely through higher pulse frequency driven by estrogen's stimulatory effect on GHRH neurons. After menopause, GH secretion falls sharply, with 24-hour GH pulse amplitude declining by approximately 70% between ages 25 and 65 in women. This is a larger age-related drop than in men on a per-decade basis.

Because women already pulse more frequently at baseline, using the DAC (long-acting) version of CJC-1295 may blunt natural pulsatility more than using modified GRF 1-29 does. Practitioners who specialize in female peptide protocols often prefer the non-DAC form for premenopausal women and reserve the DAC form for postmenopausal women where the natural pulse is already attenuated. No trial has directly compared these formulations head-to-head in women.

Epitalon: Mechanism and the Telomere Angle

Epitalon (also spelled Epithalon) is the tetrapeptide Ala-Glu-Asp-Gly. It was developed by the St. Petersburg Institute of Bioregulation and Gerontology, where Vladimir Khavinson's group published most of the foundational work from the 1980s onward. The proposed mechanisms include stimulation of telomerase activity in somatic cells, normalization of melatonin secretion via the pineal gland, and modulation of neuroendocrine function.

In a series of animal studies, Epitalon extended maximum lifespan in mice and rats, reduced tumor incidence, and restored circadian melatonin rhythms that had been disrupted by aging. One study in aging female mice showed improved estrous cycle regularity and preserved ovarian follicle counts compared to untreated controls, a finding that generated interest in potential female reproductive aging applications. The translation of that finding to perimenopausal or postmenopausal women has not been tested in any published clinical trial.

The only human data for Epitalon come from small, largely uncontrolled Russian studies showing normalization of melatonin levels in elderly subjects and modest improvements in longevity markers in long-term care populations. These studies are not registered on ClinicalTrials.gov and pre-date modern reporting standards.

How the Two Peptides Interact

The stack is not a pharmacological combination in the traditional sense. CJC-1295 and Epitalon do not share a receptor, do not compete for the same enzymatic pathway, and have no known direct pharmacokinetic interaction. The rationale for combining them is additive by mechanism, not synergistic by evidence.

The proposed logic runs as follows. CJC-1295 restores or amplifies the GH-IGF-1 axis, which supports lean tissue, sleep architecture, and metabolic rate. Epitalon, given cyclically, aims to protect cellular longevity machinery (telomeres) and normalize the circadian melatonin output that governs sleep depth. Since both peptides produce some of their reported benefits through improved deep sleep, combining them may produce a stronger sleep signal than either alone. This is the reasoning offered in practitioner forums and case series. It has not been tested in a controlled study.

Where Evidence Is Strong, Moderate, or Absent

| Claim | Evidence Type | Strength | |---|---|---| | CJC-1295 raises serum IGF-1 in humans | Phase II human trial Sackmann-Sala 2009 | Moderate | | Epitalon activates telomerase in cultured human cells | In vitro study Khavinson 2003 | Low (in vitro only) | | Either peptide improves body composition in women | No RCT | Absent | | Epitalon normalizes melatonin in elderly humans | Small uncontrolled human studies | Very low | | CJC-1295 + Epitalon together produce additive benefit | No study | Absent |

Complete Protocol: Dosing, Timing, and Cycle Structure

No published protocol exists specifically for women. What follows represents a synthesis of the available mechanistic data, the single published human CJC-1295 dose-finding trial, and practitioner-reported experience. Treat this as a starting framework, not a validated clinical protocol.

CJC-1295 Dosing for Women

Formulation choice. Modified GRF 1-29 (non-DAC) is generally preferred for premenopausal women because it preserves pulsatile GH secretion rather than producing a sustained elevation. The DAC form may be considered by postmenopausal women under clinical supervision.

Starting dose. 100 mcg subcutaneous injection, administered 30-60 minutes before sleep on an empty stomach, 3 nights per week. This timing takes advantage of the natural nocturnal GH surge. The dose-finding study by Ionescu and Frohman used 30-60 mcg/kg in mixed-sex adult cohorts, which translates to roughly 100-200 mcg for a 60-70 kg woman.

Titration. After 4 weeks at 100 mcg without side effects, some practitioners increase to 150-200 mcg. Higher doses are not better-studied and raise the risk of fluid retention and IGF-1 overshoot.

Cycle length. 8-12 weeks on, followed by a minimum 4-week break. This avoids receptor downregulation and allows assessment of baseline changes. Some practitioners use a 5-days-on, 2-days-off pattern within each week to preserve receptor sensitivity.

Injection site. Rotate subcutaneous sites: abdomen, anterior thigh, lateral upper arm. Use a 29-31 gauge, 0.5-inch insulin needle. Inject slowly.

Epitalon Dosing for Women

Route. Subcutaneous injection is most common in outpatient protocols. Intravenous administration (used in some Khavinson-era protocols) requires clinical oversight.

Dose. 5-10 mg per day subcutaneous. The Khavinson research group used 10 mg/day for 10-day courses.

Cycle structure. 10-20 consecutive days, then a 4-6 month off-period. Some practitioners run two 10-day courses per year (spring and autumn). The extended off-period is deliberate: Epitalon's proposed mechanism involves epigenetic and telomere-level changes that are thought to require time to express, and continuous use is unstudied.

Timing. Evening administration is common given the proposed relationship to pineal melatonin secretion, but no pharmacokinetic study has compared morning versus evening dosing.

Running the Stack Together: Sequencing Options

Because Epitalon is cycled in short, intensive bursts and CJC-1295 is run as a longer continuous course, two sequencing approaches are used in practice.

Option A (overlapping). Begin CJC-1295 on week 1. On weeks 2-3, add Epitalon at 5-10 mg/day for 10-14 consecutive days. Continue CJC-1295 through week 12. This is the most common approach reported in practitioner forums.

Option B (sequential). Complete a 10-day Epitalon course first, then begin a 12-week CJC-1295 cycle. The theory is that telomere priming happens first, and GH axis optimization builds on a more stable cellular foundation. No data support this order over Option A.

What to monitor. Obtain fasting IGF-1, fasting glucose, and fasting insulin before starting. Recheck IGF-1 at week 6 and week 12. IGF-1 above the age-adjusted upper reference range (generally above 250-300 ng/mL in women ages 30-60) signals that the CJC-1295 dose is too high. Thyroid function can be rechecked at cycle end; GH has bidirectional effects on thyroid hormone conversion, and women with subclinical hypothyroidism may see changes.

Life-Stage Considerations for Women

Reproductive Years (Ages 18-40)

Premenopausal women with intact estrogen production already have a more active GH axis than men the same age. Adding CJC-1295 on top of estrogen-driven GH pulsatility carries a higher theoretical risk of IGF-1 overshoot. Start at the lower end of the dose range (100 mcg) and check IGF-1 at 6 weeks. Women with PCOS should be particularly cautious: insulin resistance and compensatory hyperinsulinemia in PCOS already amplify IGF-1 signaling at the ovarian level, and further IGF-1 elevation could worsen androgen excess and anovulation.

Perimenopause (Ages 40-55)

The perimenopausal transition brings falling estrogen, disrupted sleep architecture, and a declining GH pulse. These changes are the most common reasons women in this stage seek out GH-axis peptides. Epitalon's potential to restore circadian melatonin patterns is theoretically appealing in perimenopause, where melatonin levels fall alongside estrogen. However, neither peptide has been studied in perimenopausal women in a published trial. Women managing perimenopause with FDA-approved menopausal hormone therapy (MHT) should discuss peptide stacking with their prescriber, because estrogen therapy itself significantly increases GH pulse amplitude and IGF-1, and combining MHT with CJC-1295 may push IGF-1 above reference range.

Postmenopause (Ages 55+)

Postmenopausal women have the lowest baseline GH secretion of any female life stage. The theoretical benefit-to-risk calculation for GH-axis peptides is most favorable here, but cancer-risk considerations are also most relevant. Elevated IGF-1 has been associated with increased breast cancer risk in postmenopausal women in observational data, including the Million Women Study and subsequent meta-analyses. Any postmenopausal woman considering this stack should have a current mammogram and discuss her personal breast cancer risk with her clinician before starting.

Trying to Conceive (TTC)

Women actively trying to conceive should not use this stack. The evidence for CJC-1295 or Epitalon during the follicular or luteal phase of a conception cycle is nonexistent, and both peptides act on neuroendocrine axes that govern reproductive hormone secretion. The risk of disrupting the LH surge or luteal function is real and unquantified.

Pregnancy and Lactation Safety

Both peptides are contraindicated in pregnancy. Discontinue CJC-1295 and Epitalon before attempting conception.

Pregnancy. CJC-1295 has no human pregnancy safety data. Growth hormone and IGF-1 have essential roles in placental development, and exogenous manipulation of the GHRH-GH-IGF-1 axis during organogenesis carries unquantifiable fetal risk. The FDA's pregnancy labeling framework does not include CJC-1295 or Epitalon because neither is an approved drug. Absence of a pregnancy category is not reassurance. It means no review has been conducted.

Epitalon has no human pregnancy data whatsoever. Its peptide structure gives it no inherent safety signal, but its actions on pineal and neuroendocrine function create theoretical risks during a period when fetal hypothalamic-pituitary development is occurring.

Lactation. No data exist on the transfer of CJC-1295 or Epitalon into human breast milk. Peptides are generally degraded in the GI tract and have low oral bioavailability, so an infant's systemic exposure from milk is likely low but has not been measured. Given the absence of safety data, neither peptide should be used during breastfeeding.

Contraception requirement. Any woman using this stack who does not want to become pregnant should use reliable contraception throughout the cycle and for at least 4 weeks after the last dose of CJC-1295 (to cover the extended half-life of the DAC form, if used).

Who This Stack May Be Appropriate For, and Who It Is Not

Potentially Appropriate (with clinical supervision)

• Postmenopausal women with documented low IGF-1 who are not on MHT, managed by a physician who can monitor IGF-1 and metabolic markers
• Perimenopausal women with severe sleep disruption unresponsive to standard interventions, under close clinical monitoring
• Women with physician-documented growth hormone deficiency (a condition with an FDA-approved treatment in recombinant GH; peptides are a lower-cost alternative some practitioners use off-label)

Not Appropriate

• Women who are pregnant or breastfeeding
• Women actively trying to conceive
• Women with active or personal history of cancer, particularly hormone-sensitive breast or ovarian cancer
• Women with PCOS and elevated baseline IGF-1 or androgen levels without a clinician managing the PCOS
• Women with acromegaly or any condition of GH excess
• Women with Type 1 or poorly controlled Type 2 diabetes (GH raises insulin resistance; this is well established in the GH deficiency treatment literature)
• Adolescents and women under 21, given the incomplete maturation of the GH axis

Side Effects and How They Differ for Women

CJC-1295

Water retention is the most commonly reported side effect and tends to be more pronounced in women than in men, likely because estrogen also promotes sodium retention. Carpal tunnel-like paresthesias occur with IGF-1 overshoot. Morning fatigue or grogginess can appear if dosing is too close to bedtime or the dose is too high.

Women with a history of hormonal acne may notice flares, because IGF-1 stimulates sebaceous gland activity. Women using isotretinoin or topical retinoids should discuss this with their prescriber.

Epitalon

Epitalon is generally well-tolerated in the limited human data available. Injection-site reactions (redness, mild swelling) are the most commonly reported issues. Vivid dreams are reported by some users and may relate to the proposed pineal-melatonin effect. No serious adverse events have been documented in published human studies, but sample sizes are small and follow-up periods short.

What the Evidence Gap Means for You

Women have been historically underrepresented in peptide and GH-axis research. The majority of CJC-1295 human data comes from mixed-sex cohorts where female-specific subgroup analyses were not reported. The single published dose-escalation trial of CJC-1295 with DAC enrolled both men and women but did not separate efficacy or safety outcomes by sex. Epitalon's human data comes predominantly from elderly Eastern European populations in non-peer-reviewed or minimally peer-reviewed publications.

This means that every dose recommendation above is extrapolated from general principles, not confirmed in women through controlled study. The framework offered here is a starting point for a conversation with a qualified clinician, not a substitute for one.